← Back to patent-cliff list
H001
Tier C — Watch / tradeH001
Halda Therapeutics OpCo Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AR
Indications (approved)：Venous thromboembolism, Shock, Prostate cancer
Regional status
US
-
2023-02-17
EU
-
China
Phase II
2025-01-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of H001?
Approved indications include: Venous thromboembolism, Shock, Prostate cancer.
When does the H001 patent expire?
No public expiry year is available for H001 yet; this page updates once verified.
How do I get a quote for H001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01